Revelation Biosciences Stock Performance
| REVBW Stock | USD 0.01 0.0001 1.04% |
The company holds a Beta of 0.34, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Revelation Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Revelation Biosciences is expected to be smaller as well. Revelation Biosciences right now holds a risk of 12.09%. Please check Revelation Biosciences treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to decide if Revelation Biosciences will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Revelation Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable fundamental drivers, Revelation Biosciences is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 12 M | |
| Total Cashflows From Investing Activities | -19.2 K |
Revelation | Build AI portfolio with Revelation Stock |
Revelation Biosciences Relative Risk vs. Return Landscape
If you would invest 1.30 in Revelation Biosciences on August 12, 2025 and sell it today you would lose (0.35) from holding Revelation Biosciences or give up 26.92% of portfolio value over 90 days. Revelation Biosciences is currently producing 0.0969% returns and takes up 12.0879% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Revelation, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Revelation Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revelation Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Revelation Biosciences, and traders can use it to determine the average amount a Revelation Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.008
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | REVBW |
| Negative Returns |
Estimated Market Risk
| 12.09 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.1 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Revelation Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Revelation Biosciences by adding Revelation Biosciences to a well-diversified portfolio.
Revelation Biosciences Fundamentals Growth
Revelation Stock prices reflect investors' perceptions of the future prospects and financial health of Revelation Biosciences, and Revelation Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Revelation Stock performance.
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.53 | ||||
| EBITDA | (7.95 M) | ||||
| Cash And Equivalents | 4.14 M | ||||
| Cash Per Share | 1.79 X | ||||
| Total Debt | 1.91 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 3.07 X | ||||
| Cash Flow From Operations | (18.32 M) | ||||
| Earnings Per Share | (4.77) X | ||||
| Total Asset | 6.62 M | ||||
| Retained Earnings | (40.51 M) | ||||
About Revelation Biosciences Performance
Evaluating Revelation Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Revelation Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Revelation Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company was founded in 2019 and is based in New York, New York. Revelation Biosciences is traded on NASDAQ Exchange in the United States.Things to note about Revelation Biosciences performance evaluation
Checking the ongoing alerts about Revelation Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Revelation Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Revelation Biosciences had very high historical volatility over the last 90 days | |
| Revelation Biosciences has some characteristics of a very speculative penny stock | |
| Revelation Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (15.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Revelation Biosciences has accumulated about 4.14 M in cash with (18.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Revelation Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Revelation Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Revelation Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Revelation Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Revelation Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Revelation Biosciences' stock. These opinions can provide insight into Revelation Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Revelation Stock Analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.